{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:25:10Z","timestamp":1768922710832,"version":"3.49.0"},"reference-count":49,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.3892\/ijo.2015.3231","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T07:51:02Z","timestamp":1446709862000},"page":"253-260","source":"Crossref","is-referenced-by-count":16,"title":["PF-04691502, a dual PI3K\/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas"],"prefix":"10.3892","volume":"48","author":[{"given":"DEYU","family":"CHEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHAOMING","family":"MAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUEPENG","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUTING","family":"SU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHENZHA","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEN-QING","family":"QI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"key20180107185554_b1-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: Opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20180107185554_b2-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: Variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"key20180107185554_b3-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: The path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107185554_b4-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br J Haematol"},{"key":"key20180107185554_b5-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1242\/jcs.00609","article-title":"The phosphoinositide (PI) 3-kinase family","volume":"116","author":"Foster","year":"2003","journal-title":"J Cell Sci"},{"key":"key20180107185554_b6-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1073\/pnas.91.21.10148","article-title":"Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase","volume":"91","author":"Chen","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185554_b7-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood.V88.10.3910.bloodjournal88103910","article-title":"Interleukin-4 induces association of the c-fes proto-oncogene product with phosphatidylinositol-3 kinase","volume":"88","author":"Izuhara","year":"1996","journal-title":"Blood"},{"key":"key20180107185554_b8-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0898-6568(01)00234-0","article-title":"PTEN: The down side of PI 3-kinase signalling","volume":"14","author":"Leslie","year":"2002","journal-title":"Cell Signal"},{"key":"key20180107185554_b9-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"key20180107185554_b10-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"key20180107185554_b11-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1073\/pnas.0510772103","article-title":"Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase","volume":"103","author":"Kang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185554_b12-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1126\/science.276.5320.1848","article-title":"Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase","volume":"276","author":"Chang","year":"1997","journal-title":"Science"},{"key":"key20180107185554_b13-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1073\/pnas.040560897","article-title":"Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells","volume":"97","author":"Jiang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185554_b14-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"key20180107185554_b15-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107185554_b16-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: Lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180107185554_b17-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.2010.32.7171","article-title":"Novel therapeutics for aggressive non-Hodgkin's lymphoma","volume":"29","author":"Mahadevan","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107185554_b18-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2050-7771-1-30","article-title":"Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma","volume":"1","author":"Fang","year":"2013","journal-title":"Biomark Res"},{"key":"key20180107185554_b19-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2032-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107185554_b20-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107185554_b21-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA gene in diffuse large B cell lymphoma","volume":"17","author":"Baohua","year":"2008","journal-title":"Diagn Mol Pathol"},{"key":"key20180107185554_b22-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1078-0432.CCR-08-1543","article-title":"Phospho-p70S6K\/p85S6K and cdc2\/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy","volume":"15","author":"Zhao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107185554_b23-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","article-title":"Inhibitors of B-cell receptor signaling for patients with B-cell malignancies","volume":"18","author":"Choi","year":"2012","journal-title":"Cancer J"},{"key":"key20180107185554_b24-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V99.2.584","article-title":"Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement","volume":"99","author":"Inabe","year":"2002","journal-title":"Blood"},{"key":"key20180107185554_b25-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2011-04-346601","article-title":"Dual mTORC1\/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"key20180107185554_b26-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2010.154","article-title":"The dual PI3K\/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma","volume":"24","author":"Bhende","year":"2010","journal-title":"Leukemia"},{"key":"key20180107185554_b27-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","article-title":"Role of phosphatidylinositol 3\u2032-kinase\/AKT pathway in diffuse large B-cell lymphoma survival","volume":"108","author":"Uddin","year":"2006","journal-title":"Blood"},{"key":"key20180107185554_b28-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180107185554_b29-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/mTOR dual inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"key20180107185554_b30-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.toxlet.2013.04.018","article-title":"PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells","volume":"220","author":"Wang","year":"2013","journal-title":"Toxicol Lett"},{"key":"key20180107185554_b31-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10637-013-0007-z","article-title":"Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma","volume":"31","author":"Wong","year":"2013","journal-title":"Invest New Drugs"},{"key":"key20180107185554_b32-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"e76405","DOI":"10.1371\/journal.pone.0076405","article-title":"Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis","volume":"8","author":"Devereaux","year":"2013","journal-title":"PLoS One"},{"key":"key20180107185554_b33-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"key20180107185554_b34-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"e67258","DOI":"10.1371\/journal.pone.0067258","article-title":"Antitumor efficacy of the dual PI3K\/mTOR inhibitor PF-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a PIK3CA mutation","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS One"},{"key":"key20180107185554_b35-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10637-013-0062-5","article-title":"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer","volume":"32","author":"Britten","year":"2014","journal-title":"Invest New Drugs"},{"key":"key20180107185554_b36-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107185554_b37-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","article-title":"PI3K\/p110{delta} is a novel therapeutic target in multiple myeloma","volume":"116","author":"Ikeda","year":"2010","journal-title":"Blood"},{"key":"key20180107185554_b38-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"key20180107185554_b39-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"key20180107185554_b40-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"Garc\u00eda-Garc\u00eda","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107185554_b41-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2014.06.081","article-title":"The novel mTORC1\/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells","volume":"450","author":"Lou","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107185554_b42-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-12-46","article-title":"Cell cycle-dependent activity of the novel dual PI3K-MTORC1\/2 inhibitor NVP-BGT226 in acute leukemia","volume":"12","author":"Kampa-Schittenhelm","year":"2013","journal-title":"Mol Cancer"},{"key":"key20180107185554_b43-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1038\/sj.onc.1210448","article-title":"Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis","volume":"26","author":"Suzuki","year":"2007","journal-title":"Oncogene"},{"key":"key20180107185554_b44-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2013.087171","article-title":"Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies","volume":"99","author":"Jabbour","year":"2014","journal-title":"Haematologica"},{"key":"key20180107185554_b45-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbrc.2003.09.132","article-title":"Role of PI3K\/AKT\/mTOR signaling in the cell cycle progression of human prostate cancer","volume":"310","author":"Gao","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107185554_b46-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"e53517","DOI":"10.1371\/journal.pone.0053517","article-title":"Inhibition of PI3K\/Akt pathway impairs G2\/M transition of cell cycle in late developing progenitors of the avian embryo retina","volume":"8","author":"Ornelas","year":"2013","journal-title":"PLoS One"},{"key":"key20180107185554_b47-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107185554_b48-ijo-48-01-0253","first-page":"503","article-title":"The novel dual PI3K\/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells","volume":"5","author":"Zou","year":"2012","journal-title":"Mol Med Rep"},{"key":"key20180107185554_b49-ijo-48-01-0253","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","article-title":"Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization","volume":"12","author":"Diehl","year":"1998","journal-title":"Genes Dev"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3231\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:03:54Z","timestamp":1599782634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,5]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.3892\/ijo.2015.3231"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3231","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]}}}